- Home
- SEVN vs CRBU Comparison
SEVN vs CRBU Comparison
Compare SEVN & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SEVN | CRBU |
|---|---|---|
| Founded | 1986 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medicinal Chemicals and Botanical Products |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 206.3M | 203.9M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | SEVN | CRBU |
|---|---|---|
| Price | $8.72 | $1.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $12.13 | $10.00 |
| AVG Volume (30 Days) | 108.4K | ★ 1.2M |
| Earning Date | 02-18-2026 | 03-09-2026 |
| Dividend Yield | ★ 12.93% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.04 | N/A |
| Revenue | ★ $29,408,000.00 | $9,295,000.00 |
| Revenue This Year | $0.59 | $0.22 |
| Revenue Next Year | $14.72 | $4.48 |
| P/E Ratio | $8.35 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.30 | $0.66 |
| 52 Week High | $13.44 | $3.54 |
Technical Indicators
Market Signals| Indicator | SEVN | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 43.76 | 45.46 |
| Support Level | $8.66 | $1.45 |
| Resistance Level | $8.83 | $1.65 |
| Average True Range (ATR) | 0.19 | 0.11 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 54.55 | 33.33 |
Price Performance
Historical ComparisonAbout SEVN Seven Hills Realty Trust
Seven Hills Realty Trust is a real estate investment trust. The company is engaged in the business of originating and investing in floating rate first mortgage loans secured by the middle market and transitional commercial real estate. Its primary objective is to balance capital preservation with generating risk-adjusted returns.
About CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.